Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 230 participants.
Also called NCT02089126
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 230 participants
- Sponsor
- Registry
-
NCT02089126
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- Not reported
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02089126. Randomized; triple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2016-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Gemigliptin/Glimepiride combination
- Lead sponsor
- LG Life Sciences
Record details
- Record id
cardio:ct-nct02089126- Content hash
567c8065a9ae1aa9acdc5d697bfedb08ede95a25c33c35659c0ff322e0223d07